Overview

The Effect of GD-iExo-003 in Acute Ischemic Stroke

Status:
Recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.
Phase:
Phase 1
Details
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborator:
Guidon Pharmaceutics Ltd.